Articles related to HODGKIN LYMPHOMA (HL)

The authors of this JCO study used a PET-adaptive approach to reduce the need for radiotherapy (RT) in early PET (-) disease and escalate therapy in patients with PET (+) disease. The study reports excellent outcomes for the approach, which allowed omission of radiotherapy in more than three-quarters of patients.

Second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT).